Plural Hetero Atoms In The Additional Hetero Ring Patents (Class 540/603)
-
Publication number: 20100069364Abstract: The present invention relates to substituted pyrazoline compounds, methods for their preparation, medicaments comprising these compounds as well as their use for the preparation of a medicament for the treatment of humans and animals, especially in dyslipidaemia.Type: ApplicationFiled: January 17, 2008Publication date: March 18, 2010Applicant: LABORATORIOS DEL DR. ESTEVE, S.A.Inventors: Antonio Torrens-Jover, Susana Yenes-Minguez
-
Publication number: 20100048891Abstract: Thiazolidinones of general formula (I) production thereof and use as inhibitors of polo like kinase (PLK) for the treatment of various diseases.Type: ApplicationFiled: April 29, 2009Publication date: February 25, 2010Inventors: Klause SCHULZE, Knut Eis, Lars Wortmann, Dirk Kosemund, Olaf Prien, Gerhard Siemeister, Holger Hess-Stumpp, Uwe Eberspaecher, Dominic E.A. Brittain, Imadul Islam
-
Publication number: 20100004224Abstract: The invention relates to the use of compounds having pharmacological activity towards the sigma receptor, and more particularly to 1,2,4-triazole derivatives of formula (I) to processes of preparation of such compounds and to pharmaceutical compositions comprising them.Type: ApplicationFiled: November 7, 2007Publication date: January 7, 2010Applicant: LABORATORIOS DEL DR. ESTEVE, S.A.Inventors: Nadine Jagerovic, Jose Maria Cumella-Montanchez, Maria Pilar Goya-Laza, Alberto Dordal Zueras, Maria Rosa Cuberes-Altisent
-
Publication number: 20100004265Abstract: The invention relates to compounds having pharmacological activity towards the sigma receptor, and more particularly to 1,2,3-triazole derivatives of formula (I) and to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use in therapy and prophylaxis, in particular for the treatment of psychosis or pain.Type: ApplicationFiled: November 7, 2007Publication date: January 7, 2010Inventors: Nadine Jagerovic, Cristina Ana Gomez-De La Oliva, Maria Pilar Goya-Laza, Alberto Dordal Zueras, Maria Rosa Cuberes-Altisent
-
Publication number: 20090298806Abstract: The present invention is directed to compounds represented by Formula I and pharmaceutically acceptable salts, solvates, hydrates, and prodrugs thereof which are inhibitors of Factor Xa. The present invention is also directed to and intermediates used in making such compounds, pharmaceutical compositions containing such compounds, methods to prevent or treat a number of conditions characterized by undesired thrombosis and methods of inhibiting the coagulation of a blood sample.Type: ApplicationFiled: January 5, 2009Publication date: December 3, 2009Inventors: Bing-Yan Zhu, Shawn M. Bauer, Zhaozhong J. Jia, Gary D. Probst, Yanchen Zhang, Robert M. Scarborough
-
Publication number: 20090298811Abstract: This invention relates to compounds and methods for the treatment of a condition mediated by CB1 receptor activity in a mammalian subject including a human, which comprises administering to a mammal in need of such treatment a therapeutically effective amount of the compound of formula (I) or pharmaceutically acceptable salts thereof, wherein: A, B, R1, R2 and R3 are each as described herein.Type: ApplicationFiled: September 3, 2007Publication date: December 3, 2009Inventors: Kazuo Ando, Ingrid Price Buchler, Shridhar Gajanan Hedge, Makoto Kawai, Tsutomu Masuda, Hirofumi Omura
-
Publication number: 20090286766Abstract: Provided is an agent for treating or preventing urinary frequency, urinary urgency and urinary, incontinence which are associated with overactive bladder, a lower urinary tract disease such as interstitial cystitis and chronic prostatitis accompanied by lower urinary tract pain, and various diseases accompanied by pain. A novel azolecarboxamide derivative in which an azole ring such as thioazole or oxazole is bonded to a benzene ring, pyridine ring or pyrimidine ring through carboxamide was confirmed to have a potent trkA receptor-inhibitory activity and found to be an agent for treating or preventing lower urinary tract disease and various diseases accompanied by pain, which is excellent in efficacy and safety, and thus the present invention was accomplished.Type: ApplicationFiled: April 19, 2007Publication date: November 19, 2009Applicant: ASTELLAS PHARMA INC.Inventors: Keizo Sugasawa, Kenichi Kawaguchi, Takaho Matsuzawa, Ryushi Seo, Hironori Harada, Akira Suga, Tomoaki Abe, Hidenori Azami, Shunichiro Matsumoto, Takashi Shin, Masayuki Tanahashi, Toru Watanabe
-
Publication number: 20090281084Abstract: The invention relates to phenyl-1,2,4-oxadiazolone derivatives with phenyl group and to their physiologically acceptable salts and physiologically functional derivatives showing PPARdelta agonist activity. What are described are compounds of the formula I, in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparations. The compounds are suitable for the treatment and/or prevention of disorders of fatty acid metabolism and glucose utilization disorders as well as of disorders in which insulin resistance is involved and demyelinating and other neurodegenerative disorders of the central and peripheral nervous system.Type: ApplicationFiled: May 29, 2009Publication date: November 12, 2009Applicant: SANOFI-AVENTISInventors: Patrick Bernardelli, Stefanie Keil, Matthias Urmann, Hans Matter, Wolfgang Wendler, Maike Glien, Karen Chandross, Lan Lee, Corinne Terrier, Herve Minoux
-
Publication number: 20090270372Abstract: A subject of the present Application is novel derivatives of benzimidazole and imidazopyridine which have a good affinity for certain sub-types of melanocortin receptors, in particular the MC4 receptors. They are particularly useful for treating pathological conditions and diseases in which one or more melanocortin receptors are involved. The invention also relates to pharmaceutical compositions containing said products.Type: ApplicationFiled: January 21, 2009Publication date: October 29, 2009Applicant: Societe de Conseils de Recherches etInventors: Lydie POITOUT, Valerie Brault, Carole Sackur, Roubert Pierre, Pascale Plas
-
Publication number: 20090216013Abstract: This invention relates to compounds of formula (I) which are activators of glucokinase and thus may be useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial.Type: ApplicationFiled: August 8, 2008Publication date: August 27, 2009Applicant: Novo Nordisk A/SInventors: Anthony Murray, Jesper Lau, Lone Jeppesen, Per Vedso, Michael Ankersen, Jane Marie Lundbeck, Marit Kristiansen, Maria Carmen Valcarce-Lopez, Dharma Rao Polisetti, Govindan Subramanian, Robert Carl Andrews, Daniel P. Christen, Jeremy T. Cooper, Kalpathy Chidambareswara Santhosh
-
Publication number: 20090215749Abstract: The present invention is related to thiazolidine carboxamide derivatives of formula (II) for the treatment and/or prophylaxis of preterm labor, premature birth, dysmenorrhea and for stopping labor prior to cesarean delivery.Type: ApplicationFiled: June 17, 2008Publication date: August 27, 2009Applicant: LABORATOIRES SERONO S.A.Inventors: Patrick Naxos PAGE, Catherine Jorand-Lebrun, Anna Quattropani, Vincent Pomel, Matthias Schwarz, Estelle Hamelin, Russell J. Thomas
-
Patent number: 7563784Abstract: The present invention provides C1-6alkyl-4-amino-azepan-3-one protease inhibitors and pharmaceutically acceptable salts, hydrates and solvates thereof which inhibit proteases, including cathepsin K, pharmaceutical compositions of such compounds, novel intermediates of such compounds, and methods for treating diseases of excessive bone loss or cartilage or matrix degradation, including osteoporosis; gingival disease including gingivitis and periodontitis; arthritis, more specifically, osteoarthritis and rheumatoid arthritis; Paget's disease; hypercalcemia of malignancy; and metabolic bone disease; and parasitic diseases, including malaria, by administering to a patient in need thereof one or more compounds of the present invention.Type: GrantFiled: April 25, 2006Date of Patent: July 21, 2009Assignee: SmithKline Beecham CorporationInventors: Maxwell D. Cummings, Robert W. Marquis, Jr., Yu Ru, Scott K. Thompson, Daniel F. Veber, Dennis S. Yamashita
-
Publication number: 20090181949Abstract: The present invention relates to a group of novel 1H-imidazole derivatives, to methods for the preparation of these compounds, and to pharmaceutical compositions containing one or more of these compounds as an active component. These 1H-imidazole derivatives are potent cannabinoid-CB1 receptor agonists, partial agonists or antagonists, useful for the treatment of psychiatric and neurological disorders, as well as and other diseases involving cannabinoid neurotransmission. The compounds have the general formula (I) wherein R and R1-R4 have the meanings given in the specification.Type: ApplicationFiled: September 2, 2008Publication date: July 16, 2009Inventors: Cornelis G. KRUSE, Josephus H.M. LANGE, Arnoldus H.J. HERREMANS, Herman H. VAN STUIVENBERG
-
Publication number: 20090170832Abstract: Disclosed is a compound useful as a type I 11?hydroxysteroid dehydrogenase inhibitor. A compound represented by the formula: a pharmaceutically acceptable salt or solvate thereof, wherein R1 is optionally substituted alkyl or the like, one of R2 and R4 is a group of formula: —Y—R5, wherein Y is —O— or the like, R5 is substituted alkyl (the substituent is optionally substituted cycloalkyl or the like), optionally substituted branched alkyl or the like, the other of R2 and R4 is hydrogen or optionally substituted alkyl, R3 is a group of formula: —C(?O)-Z-R6, wherein Z is —NR7— or —NR7—W—, R6 is optionally substituted cycloalkyl or the like, R7 is hydrogen or optionally substituted alkyl, W is optionally substituted alkylene, X is ?N— or the like, with the proviso that compounds wherein R2 is 2-(morphorino)ethoxy, R3 is N-(1-adamantyl)carbamoyl and R1 is benzyl are excluded.Type: ApplicationFiled: November 20, 2006Publication date: July 2, 2009Applicant: SHIONOGI & CO., LTD.Inventors: Noriyuki Kurose, Mikayo Hayashi, Tomoyuki Ogawa, Koji Masuda, Eiichi Kojima
-
Publication number: 20090163464Abstract: Compounds of formula (I) are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands. Also disclosed are pharmaceutical compositions of compounds of formula (I), methods for using such compounds and compositions, and a process for preparing the compounds.Type: ApplicationFiled: December 17, 2008Publication date: June 25, 2009Applicant: Abbott LaboratoriesInventors: Lawrence A. Black, Marlon D. Cowart, Gregory A. Gfesser, Brian D. Wakefield, Robert J. Altenbach, Huaqing Liu, Chen Zhao, Gin C. Hsieh
-
Publication number: 20090156582Abstract: The present invention provides a pyrazole compound represented by the formula (I): wherein ring A0 is a pyrazole ring optionally further having 1 or 2 substituents; Ra is a substituted carbamoyl group; and Rb is an optionally substituted acylamino group, or a salt thereof or a prodrug thereof, which is useful as an agent for the prophylaxis or treatment of GSK-3? related pathology or disease, and a GSK-3? inhibitor including same.Type: ApplicationFiled: February 9, 2006Publication date: June 18, 2009Inventors: Tetsuya Tsukamoto, Takeshi Yamamoto, Ryosuke Tokunoh, Tomohiro Kawamoto, Masahiro Okura, Masakumi Kori, Katsuhito Murase
-
Publication number: 20090149443Abstract: Compounds of formula (I): in which A, B, X, Ar1, R8 and R4 have any of the meanings given in the specification, are inhibitors of p38 useful in the treatment and prevention of various disorders mediated by p38.Type: ApplicationFiled: March 27, 2007Publication date: June 11, 2009Inventors: Mark C. Munson, Kevin W. Hunt, Christopher T. Clark, Ganghyeok Kim, Laurence E. Burgess, James P. Rizzi
-
Publication number: 20090143364Abstract: and the pharmaceutically acceptable salts and esters thereof, wherein X1, X2, X3, Y1, Y2 and R are described herein inhibit the interaction of MDM2 protein with a p53-like peptide and hence have anti proliferative activity.Type: ApplicationFiled: February 5, 2009Publication date: June 4, 2009Inventors: Nader Fotouhi, Gregory Jay Haley, Klaus B. Simonsen, Binh Thanh Vu, Stephen Evan Webber
-
Publication number: 20090137560Abstract: The present invention relates to compounds of formula (I), methods for their preparation, medicaments comprising these compounds as well their use in the manufacture of a medicament for the treatment of humans and animals.Type: ApplicationFiled: March 5, 2007Publication date: May 28, 2009Inventors: Rosa Cuberes-Altisent, Joerg Holenz
-
Patent number: 7524838Abstract: The present invention relates to the novel derivatives of formula (I) in which A is, if it is present, a (C1-C6) alkyl, a (C3-C6) alkenyl, a (C3-C6) alkynyl, a (C3-C7) cycloalkyl or a (C5-C7) cycloalkenyl, R1 is an NR6R7, (C4-C7) azacycloalkyl, (C5-C7) azacycloalkenyl, (C5-C9) azabicycloalkyl or (C5-C9) azabicycloalkenyl group; A-R1 is such that the nitrogen of R1 and the nitrogen in the 1-position of the pyrazole are necessarily separated by at least two carbon atoms, R3 is an H, halogen, OH, SH, NH2, ORc, SRc, SORa, SO2Ra, NHCHO, NRaRb, NHC(O)Ra, NHC(S)Ra or NHSO2Ra, R4 is an aryl or heteroaryl; and R5 is an H, halogen, CF3, CHF2, CH2F, linear or branched (C1-C6) alkyl or (C3-C7) cycloalkyl, to their racemates, enantiomers and diastereoisomers and to their mixtures, their tautomers and to their pharmaceutically acceptable salts.Type: GrantFiled: November 24, 2004Date of Patent: April 28, 2009Assignee: Aventis Pharma S.A.Inventors: Arielle Genevois-Borella, Jean-Luc Malleron, Jean Bouquerel, Gilles Doerflinger, Andrees Bohme, Gaetan Touyer, Jean-Francois Sabuco, Corrine Terrier, Serge Mignani, Michel Evers, Youssef El-Ahmad
-
Publication number: 20090105217Abstract: Novel oxadiazole derivatives of formula (I) having pharmacological activity, processes for their preparation, compositions containing them and their use in the treatment of neurological, psychiatric disorders and gastrointestinal disorders through modulation of the nicotinic ?7 receptor.Type: ApplicationFiled: May 29, 2007Publication date: April 23, 2009Inventors: Frank Teen Coppo, Emma S.L. Maskell, Sally Redshaw, John Skidmore, Robert William Ward, David Matthew Wilson
-
Publication number: 20090081123Abstract: Tricyclic pyrazole derivatives of the following formula (I) having affinity for the cannabinoidergic CB1 and/or CB2 receptors: wherein: A represents a group selected from one of the following: (CH2)t—, —(CH2)—S(O)z—, or —S(O)z—(CH2)—, B is a heteroaryl, optionally substituted; R is a group selected from the following: alkyl, aryl, arylalkyl or arylalkenyl, not substituted or having from one to four substituents, equal to or different from each other; R? is a group selected from the following: an ether group of formula —(CH2)—O—(CH2)v—R?, a ketonic group of formula —C(O)-Z?, wherein Z? is as defined below; a substituent having an hydroxyl function of formula —CH(OH)-Z?; an amide substituent of formula —C(O)—NH-T?.Type: ApplicationFiled: December 8, 2008Publication date: March 26, 2009Applicant: CeNeRx BioPharmaInventors: Paolo LAZZARI, Stefania RUIU, Gerard Aime PINNA, Gabriele MURINEDDU
-
Publication number: 20090075979Abstract: Compounds having the structure of Formula (I), including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In the compounds of Formula (I), B or R2 is a phenyl group which has an ortho amine or aminomethyl substituent which is further substituted, and the other of B or R2 is also a cyclic group.Type: ApplicationFiled: December 29, 2006Publication date: March 19, 2009Inventors: Amjad Ali, Zhijian Lu, Peter J. Sinclair, Gayle E. Taylor, Christopher F. Thompson, Cameron J. Smith, Adrian A. Dowst, Yi-Heng Chen
-
Publication number: 20090060853Abstract: The Use, as a UV filter, of a compound of formula R1 and R2 are each independently of the other hydrogen; unsubstituted or halo-, amino-, mono- or di-C1-C5alkylamino-, cyano- or C1-C5alkoxy-substituted C1-C22alkyl, C5-C10cycloalkyl, carboxy-C1-C22alkyl, carboxy-C6-C10aryl, C6-C10aryl, C6-C10aryl-C1-C5alkyl; carbamoyl; or sulfamoyl; or R1 and R2, together with the nitrogen atom linking them, form a 5- to 7-membered heterocyclic radical; and R3 is hydrogen; or C1-C22alkyl; and R4 is hydrogen; hydroxy; C1-C22alkyl; or C1-C22alkoxy; is described. The compounds of formula (1) are suitable especially as UV filters in cosmetic preparations.Type: ApplicationFiled: September 18, 2008Publication date: March 5, 2009Inventors: Barbara Wagner, Thomas Ehlis, Sebastien Mongiat, Kai Eichin
-
Publication number: 20090062259Abstract: The present invention relates to compounds according to formula (I), a process for preparing them, the intermediate compounds of the process and the use of the compounds in the manufacture of a medicament for use in treating diseases such as ARDS, pulmonary emphysema, bronchitis, bronchiectasis, COPD, asthma and rhinitis. The compounds are beta adrenoreceptor agonists.Type: ApplicationFiled: March 12, 2007Publication date: March 5, 2009Applicant: ASTRAZENECA ABInventors: Lilian Alcaraz, Andrew Lister, Garry Pairaudeau
-
Publication number: 20090023707Abstract: The present invention provides a compound of formula I: and the use thereof for the treatment of a central nervous system disorder related to or affected by the histamine-3 receptor.Type: ApplicationFiled: July 15, 2008Publication date: January 22, 2009Applicant: WyethInventors: Jonathan Laird Gross, Albert Jean Robichaud, Marla Jean Williams, Alessandro Mazzacani
-
Publication number: 20090005364Abstract: The present invention relates to compounds of formula (I) wherein R1, R2, x, X, Y and B are as defined in the description for the treatment of muscarinic acetylcholine receptor mediated diseases, in particular M3 muscarinic receptor mediated diseases.Type: ApplicationFiled: December 22, 2005Publication date: January 1, 2009Inventors: Ilaria Peretto, Francesca Scarpitta, Elena La Porta, Luca Raveglia, Giuseppe Arnaldo Maria Giardina, Bruno Pietro Imbimbo, Andrea Rizzi, Gino Villetti
-
Patent number: 7462717Abstract: The invention concerns substituted tricyclic isoxazoline derivatives, more in particular tricyclic dihydrobenzopyranoisoxazoline, dihydroquinolinoisoxazoline, dihydronaphthalenoisoxazoline and dihydrobenzothiopyranoisoxazoline derivatives substituted on at least one of the C6- and C9-positions of the phenylpart of the tricyclic moiety with a selected radical, according to Formula (I) wherein X=CH2, N—R7, S or O, R1, R2, R14 and R15 are certain specific substituents, with the proviso that at least one of R14 and R15 is not hydrogen, Pir is preferably an optionally substituted piperidinyl or piperazinyl radical and R3 represents an optionally substituted aromatic homocyclic or heterocyclic ring system including a partially or completely hydrogenated hydrocarbon chain of maximum 6 atoms long with which the ring system is attached to the Pir radical and which may contain one or more heteroatoms selected from the group of O, N and S; a process for their preparation, pharmaceutical compositions comprising themType: GrantFiled: August 19, 2003Date of Patent: December 9, 2008Assignee: Janssen Pharmaceutica N.V.Inventors: José Ignacio Andrés-Gil, Manuel Jesús Alcázar-Vaca, Maria Encarnacion Matesanz-Ballesteros, Margaretha Henrica Maria Bakker, Antonius Adrianus Hendrikus Petrus Megens
-
Publication number: 20080286265Abstract: The present invention relates to compounds of Formula (I), methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating a condition including but not limited to ankylosing spondylitis, artherosclerosis, arthritis (such as rheumatoid arthritis, infectious arthritis, childhood arthritis, psoriatic arthritis, reactive arthritis), bone-related diseases (including those related to bone formation), breast cancer (including those unresponsive to anti-estrogen therapy), cardiovascular disorders, cartilage-related disease (such as cartilage injury/loss, cartilage degeneration, and those related to cartilage formation), chondrodysplasia, chondrosarcoma, chronic back injury, chronic bronchitis, chronic inflammatory airway disease, chronic obstructive pulmonary disease, diabetes, disorders of energy homeostasis, gout, pseudogout, lipid disorders, metabolic syndrome, multiple myeloma, obesity, osteoarthritis, osteogenesis imperfecta, osteolytic bone metastasis, osteomalacType: ApplicationFiled: March 6, 2008Publication date: November 20, 2008Inventors: Michael Gaul, Lily Lee Searle, Dionisios Rentzeperis
-
Publication number: 20080269201Abstract: The present invention relates to Azepane- or Azocane-substituted substituted pyrazoline compounds of formula (I), methods for their preparation, medicaments comprising these compounds as well as their use for the preparation of a medicament for the treatment of humans and animalsType: ApplicationFiled: July 17, 2006Publication date: October 30, 2008Applicant: LABORATORIOS DEL DR. ESTEVE, S.A.Inventors: Antonio Torrens Jover, Susana Yenes Minguez
-
Publication number: 20080255094Abstract: The present invention is related to thiazolidine carboxamide derivatives of formula (II) for the treatment and/or prophylaxis of preterm labor, premature birth, dysmenorrhea and for stopping labor prior to cesarean delivery.Type: ApplicationFiled: June 17, 2008Publication date: October 16, 2008Applicant: LABORATOIRES SERONO S.A.Inventors: Patrick Naxos PAGE, Catherine Jorand-Lebrun, Anna Quattropani, Vincent Pomel, Matthias Schwarz, Estelle Hamelin, Russell J. Thomas
-
Publication number: 20080249301Abstract: The present invention provides a process for preparing benzimidazole thiophene compounds of formula (I). Intermediates used in the process are also claimed.Type: ApplicationFiled: August 28, 2006Publication date: October 9, 2008Inventors: Keith Hornberger, Mui Cheung, Mark Andrew Pobanz, Kyle Allen Emmitte, Kevin Wayne Kuntz, Jennifer Gabriel Badiang
-
Patent number: 7429607Abstract: The present invention relates to compounds of formula I: wherein one of R1 and R4 is selected from the group consisting of H, and optionally substituted C1-6 alkyl, C3-7 cycloalkyl, C3-7 cycloalkyl-C1-4 alkyl, and phenyl-C1-4 alkyl; and the other of R1 and R4 is an optionally substituted C9-14 aryl group; R2 and R3 are either: (i) independently selected from H, R, R?, SO2R, C(?O)R, (CH2)nNR5R6, where n is from 1 to 4 and R5 and R6 are independently selected from H and R, where R is optionally substituted C1-4 alkyl, and R? is optionally substituted phenyl-C1-4 alkyl, or (ii) together with the nitrogen atom to which they are attached, form an optionally substituted C5-7 heterocyclic group; and their use as pharmaceuticals, in particular for treating conditions alleviated by the antagonism of a 5-HT2B receptor.Type: GrantFiled: February 12, 2003Date of Patent: September 30, 2008Assignee: Asterand UK LimitedInventors: Alexander William Oxford, Richard Anthony Borman, Robert Alexander Coleman, Kenneth Lyle Clark, George Hynd, Janet Ann Archer, Amanda Aley, Neil Victor Harris
-
Patent number: 7414048Abstract: The present invention is concerned with the compounds of formula wherein m, n and p are each independently 0 or 1 and q is 0, 1, 2, 3, 4 or 5; -A1=A2-A3=A4- is a pyridinylidene, pyridazinylidene, pyrimidinylidene, pyrazinylidene or phenylidene; B represents an amide, ketone or oxadiazole; D represents Ar or Het; Q represents a covalent direct bond or a ketone, —N—, —O—, —CR5R6—, amide, ethenyl, imine, sulfonyl, sulfinyl, 3-oxobutenyl, pyrazole, isoxazole or thiazole; L represents Ar or Het; R1 represents hydrogen, halo, hydroxy, C(2-6)alkenyl, C(2-6)alkynyl, C(3-6)cycloalkyl, C(3-6)cycloalkenyl, cyano, guanidine, nitro, NR17R18, an optionally substituted C(1-6)alkyl or C(1-6)alkyloxy; R2 and R3 each independently represent hydrogen, halo, C(1-6)alkyloxy or an optionally substituted C(1-6)alkyl; R5 and R6 each independently represent hydrogen, hydroxy, halo, an optionally substituted C(1-6)alkyl, C(2-6)alkenyl, C(2-6)alkynyl, C(3-6)cycloalkyl, C(3-6)cycloalkenyl, C(1-6)alkyloxy, cyano, (C?O)R25, (C—O)OR16,Type: GrantFiled: March 31, 2003Date of Patent: August 19, 2008Assignee: Janssen Pharmaceutica, N.V.Inventors: Eddy Jean Edgard Freyne, José Ignacio Andrés-Gil, Frederik Dirk Deroose, Davy Petrus Franciscus Maria Petit, Maria Encarnacion Matesanz-Ballesteros, Rosa Maria Alvarez Escobar
-
Patent number: 7405209Abstract: The present invention provides 4-amino-azepan-3-one protease inhibitors and pharmaceutically acceptable salts, hydrates and solvates thereof which inhibit proteases, including cathepsin K, pharmaceutical compositions of such compounds, novel intermediates of such compounds, and methods for treating diseases of excessive bone loss or cartilage or matrix degradation, including osteoporosis; gingival disease including gingivitis and periodontitis; arthritis, more specifically, osteoarthritis and rheumatoid arthritis; Paget's disease; hypercalcemia of malignancy; and metabolic bone disease, comprising inhibiting said bone loss or excessive cartilage or matrix degradation by administering to a patient in need thereof a compound of the present invention.Type: GrantFiled: June 14, 2005Date of Patent: July 29, 2008Assignees: SmithKline Beecham Corporation, SmithKline Beecham p.l.c.Inventors: Robert Wells Marquis, Jr., Yu Ru, Daniel Frank Veber, Maxwell David Cummings, Scott Kevin Thompson, Dennis Shinji Yamashita
-
Patent number: 7393842Abstract: One aspect of the invention is concerned with cannabimimetic pyrazole analogs. Another aspect of the invention is concerned with new and improved pyrazole analogs having high affinities and/or selectivities for the CB1 cannabinoid receptor. A further aspect of the invention is concerned with pharmaceutical preparations employing the inventive analogs and methods of administering therapeutically effective amounts of the inventive analogs to provide a physiological effect.Type: GrantFiled: March 1, 2004Date of Patent: July 1, 2008Assignee: University of ConnecticutInventors: Alexandros Makriyannis, Qian Liu, Rajesh Thotapally
-
Publication number: 20080153810Abstract: The present invention relates to novel compounds, in particular, novel indazole that may be used as melanin concentrating hormone receptor ligands, methods of preparing such compounds, compositions containing such compounds, and methods of using such compounds to treat MCH related disorders.Type: ApplicationFiled: November 14, 2007Publication date: June 26, 2008Applicant: Forest Laboratories Holdings LimitedInventors: Matthew Ronsheim, Gian-Luca Araldi
-
Publication number: 20080146542Abstract: The present invention concerns hydrazinocarbonyl-thieno[2,3-c]pyrazoles of formula (I): wherein R1, R3, R4, are R5 are as defined in the disclosure; their preparation method, compositions containing the same and their use for the treatment of pathological conditions, in particular as anticancer agents.Type: ApplicationFiled: August 29, 2007Publication date: June 19, 2008Applicant: Aventis Pharma S.A.Inventors: Claude BARBERIS, Jean-Christophe CARRY, Gilles DOERFLINGER, Dominique BARBALAT-DAMOUR, Francois CLERC, Herve MINOUX
-
Publication number: 20080146539Abstract: The present invention relates to new substituted carboxylic acid amides of general formula wherein A, B and R1 to R5 are defined as in claim 1, the tautomers, the enantiomers, the diastereomers, the mixtures thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, which have valuable properties.Type: ApplicationFiled: December 19, 2007Publication date: June 19, 2008Applicant: Boehringer Ingelheim International GmbHInventors: Henning PRIEPKE, Kai Gerlach, Roland Pfau, Norbert Hauel, Iris Kauffmann-Hefner, Georg Dahmann, Herbert Nar, Sandra Handschuh, Wolfgang Wienen, Annette Schuler-Metz
-
Publication number: 20080139533Abstract: The present invention relates to a compound of formula I, wherein R1 is selected from the group consisting of hydrogen and lower alkyl; each R2 is independently selected from the group consisting of hydrogen and lower alkyl; each R3 is independently selected from the group consisting of hydrogen, lower alkyl, lower alkoxy, phenyloxy, benzyloxy, halogen and lower alkyl substituted by halogen; R4 is selected from the group consisting of hydrogen and lower alkyl; X is selected from the group consisting of —CH2—, —CH— and —O—; Y is selected from the group consisting of —CH2—, —CH2CH2—, —CH— and a bond; with the proviso that, when X is —O—, Y is —CH2—; Z is selected from the group consisting of —CH2— and —CH—; m is 1 or 2; and n is 1 or 2. The invention relates also to a pharmaceutically-acceptable acid-addition salt of such a compound, methods for making the compound, and a composition comprising such a compound.Type: ApplicationFiled: November 13, 2007Publication date: June 12, 2008Inventors: Guido Galley, Katrin Groebke Zbinden, Roger Norcross, Henri Stalder
-
Publication number: 20080119458Abstract: The present invention provides a compound of formula I and the use thereof for the treatment of a central nervous system disorder related to or affected by the histamine-3 receptor: wherein the variables are described in the specification.Type: ApplicationFiled: October 5, 2007Publication date: May 22, 2008Applicant: WyethInventors: William Ronald Solvibile, Ji-ln Kim, Marla Jean Williams, Jonathan Laird Gross, Albert Jean Robichaud
-
Patent number: 7323456Abstract: A compound of formula (I) (wherein all symbols are as defined in the specification) and a salt thereof, and peroxisome proliferator activated receptor regulator comprising thereof as active ingredient. Because a compound of formula (I) have an activity of regulating peroxisome proliferator activated receptor regulator, the compound of formula (I) is useful as a hypoglycemic agent, a hypolipidemic agent, a preventive and/or treatment agent for diseases associating metabolic disorders (diabetes, obesity, syndrome X, hypercholesterolemia, hyperlipoproteinemia, etc.), hyperlipemia, atherosclerosis, hypertension, circulatory diseases, overeating, ischemic heart diseases, etc., an HDL cholesterol-elevating agent, an LDL cholesterol and/or VLDL cholesterol-lowering agent and a drug for relief from risk factors of diabetes or syndrome X.Type: GrantFiled: November 11, 2002Date of Patent: January 29, 2008Assignee: Ono Pharmaceutical Co., Ltd.Inventors: Hisao Tajima, Yoshisuke Nakayama
-
Publication number: 20070281922Abstract: The present invention provides a compound of formula I and the use thereof for the treatment of a central nervous system disorder related to or affected by the 5-HT6 receptor.Type: ApplicationFiled: May 31, 2007Publication date: December 6, 2007Applicant: WyethInventors: Kevin Liu, Jennifer Rebecca Lo, Albert Jean Robichaud, Hassan Mahmoud Elokdah
-
Patent number: 7304052Abstract: The present invention relates to compounds of formula (I) their prodrugs, N-oxides, addition salts, quaternary amines and stereochemically isomeric forms, wherein the bivalent radical -{circle around (A)}- represents a saturated or an unsaturated homopiperidinyl having one double bond, and wherein said bivalent radical -{circle around (A)}- is substituted with R2 being hydrogen, hydroxy, C1-4alkyl, or C1-4alkyloxy; -a1=a2-a3=a4- represents an optionally substituted bivalent radical; R1 is hydrogen, C1-6alkyl, aryl1, C1-6alkyl substituted with aryl1, C1-4alkyloxycarbonyl, aryl1carbonyl, aryl1C1-6alkylarbonyl C1-4alkylcarbonyl, trifluoromethyl, trifluoromethylcarbonyl, C1-6alkylsulfonyl, aryl1sulfonyl, methanesulfonyl, benzenesulfonyl, trifluoromethanesulfonyl, dimethylsulfamoyl; X represents O, S or NR3, wherein R3 is hydrogen, C1-6alkyl, methanesulfonyl, benzenesulfonyl, trifluoromethanesulfonyl, dimethylsulfamoyl, C1-4alkyl substituted with aryl2 and optionally with hydroxy, C1-4alkylcarbonylC1-4alkyl suType: GrantFiled: December 14, 2000Date of Patent: December 4, 2007Assignee: Janssen Pharmaceuitca N.V.Inventors: Frans Eduard Janssens, Jérôme Emile Georges Guillemont, François Maria Sommen
-
Patent number: 7304048Abstract: The invention is directed to methods to inhibit p38-? kinase using compounds containing an aromatic system coupled through a 7-membered heterocycle to an indole-type system.Type: GrantFiled: May 28, 2002Date of Patent: December 4, 2007Assignee: Scios, Inc.Inventors: Babu J. Mavunkel, Sarvajit Chakravarty, John J. Perumattam, Sundeep Dugar, Qing Lu, Xi Liang
-
Publication number: 20070238724Abstract: The present invention provides a compound of formula I and the use thereof for the treatment of a central nervous system disorder related to or affected by the 5-HT6 receptor.Type: ApplicationFiled: April 4, 2007Publication date: October 11, 2007Applicant: WyethInventors: Kevin Liu, Albert Jean Robichaud, Jennifer Rebecca Lo, Hassan Mahmoud Elokdah
-
Patent number: 7273857Abstract: Benzimidazolidinone derivative compounds, which increase acetylcholine signaling or effect in the brain, and highly selective muscarinic agonists, particularly for the M1 and/or M4 receptor subtypes, pharmaceutical compositions comprising the same, as well as methods of treating psychosis using these compounds are disclosed.Type: GrantFiled: May 3, 2006Date of Patent: September 25, 2007Assignee: ACADIA Pharmaceuticals Inc.Inventors: Nicholas Michael Kelly, Kristian Norup Koch, Bo-Ragnar Tolf
-
Patent number: 7265103Abstract: The invention concerns substituted amino isoxazoline derivatives, more in particular tricyclic dihydrobenzopyranoisoxazoline, dihydroquinolinoisozazoline, dihydronaphthalenoisoxazoline and dihydrobenzothiopyranoisoxazoline derivatives substituted on the phenylpart of the tricyclic moiety with primary, secondary and/or tertiary amino groups, according to Formula (I) wherein X=CH2, N—R7, S or O, R1, R2 and R3 are certain specific substituents, with the proviso that at least one of R1 and R2 is an amino radical of formula N—R10R11 wherein R10 and R11 are each a variety of radicals, Pir is an optionally substituted piperidyl or piperazyl radical and R3 represents an optionally substituted aromatic homocyclic or heterocyclic ring system including a partially or completely hydrogenated hydrocarbon chain of maximum 6 atoms long with which the ring system is attached to the Pir radical and which may contain one or more heteroatoms selected from the group of O, N and S; a process for their preparation, pharmaceutiType: GrantFiled: March 27, 2003Date of Patent: September 4, 2007Assignee: Janssen Pharmaceutica NV.Inventors: José Ignacio Andrés-Gil, Manuel Jesús Alcázar-Vaca, Margaretha Henrica Maria Bakker, Ana Isabel De Lucas Olivares
-
Patent number: 7238696Abstract: The present invention provides a compound of formula I and the use thereof in the therapeutic treatment of disorders related to or affected by the 5-HT6 receptorType: GrantFiled: February 13, 2004Date of Patent: July 3, 2007Assignee: WyethInventors: Ronald Charles Bernotas, Yinfa Yan, Albert Jean Robichaud, Guangcheng Liu
-
Patent number: 7229987Abstract: The present invention relates to a melanin concentrating hormone antagonist compound of formula I: (I); or a pharmaceutically acceptable salt, solvate, enantiomer or prodrug thereof useful in the treatment, prevention or amelioration of symptoms associated with obesity and related diseases.Type: GrantFiled: May 6, 2003Date of Patent: June 12, 2007Assignee: Eli Lilly and CompanyInventors: Jochen Ammenn, James Ronald Gillig, Lawrence Joseph Heinz, Philip Arthur Hipskind, Michael Dean Kinnick, Yen-Shi Lai, John Michael Morin, Jr., James Arthur Nixon, Carsten Ott, Kenneth Allen Savin, Theo Schotten, Lawrence John Slieker, Nancy June Snyder, Michael Alan Robertson